A campaign of tuberculin testing in standard fashion, followed by BCG vaccination in those giving an inadequate reaction, was carried out on all children in the Bas-Rhin department in France in their first primary school year for the year 1976-1977. Of 15,560 pupils enrolled 64.5 percent had already had at least one BCG vaccination. 12,820 had the standard test, the remaining 2,740 were either absent or parents refused permission. 27.8 percent of those vaccinated had an indurated area of more than 4 mm diameter, compared to 7.4 percent among those not vaccinated. 9,517 children were vaccinated or revaccinated during the campaign, by means of scarification of intradermal injection. 4,472 had a standard post-vaccine test during the following school-year: a diameter of induration of 4 mm or less was found in 28.9 percent. The proportion varied according to the doctors who had vaccinated them but was lower among the children vaccinated by intradermal injection.

Download full-text PDF

Source

Publication Analysis

Top Keywords

bcg vaccination
12
primary school
8
children bas-rhin
8
percent vaccinated
8
children vaccinated
8
intradermal injection
8
vaccinated
5
[tuberculin screening
4
screening bcg
4
vaccination primary
4

Similar Publications

Bovine tuberculosis is mainly caused by Mycobacterium bovis. Bacillus Calmette-Guérin (BCG) is an attenuated strain of M. bovis which provides variable disease protection.

View Article and Find Full Text PDF

An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.

Pathogens

January 2025

Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil.

The COVID-19 pandemic has posed a significant threat to global health systems, with extensive impacts across many sectors of society. The pandemic has been responsible for millions of deaths worldwide since its first identification in late 2019. Several actions have been taken to prevent the disease, including the unprecedented fast development and global vaccination campaigns, which were pivotal in reducing symptoms and deaths.

View Article and Find Full Text PDF

Background: While the clinical application of SII-ONCO-Bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is well established in Greece, there is a lack of real-world data on its effectiveness and safety. This retrospective, observational, multicenter, chart-review study aims to provide real-life data on the effectiveness and safety of SII-ONCO-BCG in patients with intermediate- and high-risk NMIBC.

Methods: From January 2016 to December 2023, medical records from six hospital centers were reviewed for adult patients with histologically confirmed stage Ta or T1 NMIBC (with or without carcinoma in situ [CIS]) who received at least one maintenance course of SII-ONCO-BCG after induction.

View Article and Find Full Text PDF

Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.

Iran J Basic Med Sci

January 2025

Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran.

Objectives: Adjuvants are some of the most important components used for vaccine formulation. In addition, the efficacy of vaccines is highly dependent on the nature of the adjuvants used. Therefore, new adjuvant formulations may help develop more potent vaccines.

View Article and Find Full Text PDF

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol.

Syst Rev

January 2025

Department of Medicine, Division of Infectious Diseases, Duke University, 148 Hanes House, 315 Trent Dr, Durham, NC, 27710, USA.

Background: Although intravesical Bacillus Calmette-Guerin (BCG) immunotherapy usually exhibits a favorable safety profile, it can lead to the development of BCG infections, both localized and disseminated. Understanding of BCG infections following intravesical BCG immunotherapy is limited because of the lack of consensus definitions of BCG infections and limited post-instillation follow-up. We aim to perform a systematic review of the literature of BCG infections following intravesical BCG immunotherapy to elucidate the epidemiology, risk factors, and outcomes of BCG infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!